SETD2 and cancer: Interestingly, a pathogenic point mutation observed in cancer (R2510H) in the SRI domain of human SETD2 impairs its ability to methylate α-tubulin at lysine 40 during mitosis, whereas global methylation of H3K36 is unaffected by this mutation (Park et al., 2016).